Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma: Long term results of a phase II study

Cancer

Volumn 89, Issue 7, 2000, Pages 1547-1554

  Papadimitriou, Christos A ^a,c   Moulopoulos, Lia A ^b   Vlahos, Georgios ^a   Voulgaris, Zannis ^a   Kiosses, Evangelos ^a   Georgoulias, Nikolaos ^a   Gika, Dimitra ^a   Diakomanolis, Emmanuel ^a   Michalas, Stylianos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

Cisplatin; Epirubicin; Epithelial ovarian carcinoma; Paclitaxel

Indexed keywords

CISPLATIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LAPAROTOMY; MYALGIA; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0034306857     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001001)89:7<1547::AID-CNCR19>3.0.CO;2-P     Document Type: Article

References (48)

1. Chemotherapy in ovarian carcinoma: Present role and future prospects
2. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
3. Long-term follow up and prognostic factor analysis in advanced ovarian carcinoma. The Gynecologic Oncology Group experience
4. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
5. New therapy for ovarian cancer
6. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - A new standard of care?
7. The role of anthracyclines in epithelial ovarian cancer
8. Reporting results of cancer treatment
9. The calculation of received dose intensity
10. The description of chemotherapy delivery options and pitfalls
11. One-sample multiple testing procedure for phase II clinical trials
12. Non-parametric estimation from incomplete observations
13. Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators
14. Updated analysis shows highly significantly improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial
15. ICON 2 and ICON 3 data in previously untreated ovarian cancer: Results to date
16. Paclitaxel-cisplatin vs paclitaxel-carboplatin in previously untreated ovarian cancer
17. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
18. Cisplatin/paclitaxel vs carboplat in/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial
19. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): A Hellenic Co-Operative Group Study
20. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
21. Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
22. Impact of doxorubicin on survival in advanced ovarian cancer
23. Meta-analyses of chemotherapy regimens for ovarian carcinoma: A reassesment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide
24. Treatment of advanced ovarian cancer: A randomized trial comparing adriamycin or 4 epi-adriamycin in combination with cisplatin and cyclophosphamide
25. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma
26. Randomized trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4-epi-doxorubicin in the treatment of advanced ovarian cancer
27. Cisplatin, epirubicin and paclitaxel in uterine adenocarcinoma
28. Phase I trial of dose-escalated epirubicin (E), and paclitaxel (T), in combination with cisplatin(P) + G-CSF in advanced ovarian cancer (AOC)
29. The addition of ifosfamide or epirubicin to paclitaxel (T)/cisplatin (P) regimen in epithelial ovarian cancer (EOC): A randomized phase II study
30. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer (AOC). A phase I/II study
31. Carboplatinum, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer
32. Epidoxorubicin (EPIDOX), carboplatin (CBDCA) and paclitaxel (PTX) in advanced epithelial ovarian cancer (AEOC)
33. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group
34. Epirubicin/paclitaxel/carboplatin vs paclitaxel/carboplatin as first-line treatment in ovarian cancer: Results of a safety interium analysis of the AGO-GINEGO intergroup trial
35. Sequence of taxol and cisplatin: A phase I pharmacologic study
36. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer
37. Phase I trial of escalating doses of paclitaxel (TAX) combined with fixed doses of cisplatin (CIS) and doxorubicin (DOX) in patients with advanced gynecologic malignancies: A Gynecologic Oncology Group (GOG) trial
38. A phase I study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer
39. G-CAT (G-CSF, cis/carboplatin, adriamycins and taxol) for advanced ovarian cancer: Active but toxic
40. Prognostic value of CA 125 in advanced ovarian cancer
41. A risk model for ovarian carcinoma patients using CA 125. Time to normalization renders second-look laparotomy redundant
42. Use of tumor markers in monitoring the course of ovarian cancer
43. Early serum CA 125 response and outcome in epithelial ovarian cancer
44. Use of CA 125 response to predict survival parameters of patients with advanced ovarian carcinoma
45. CA 125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG) study
46. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
47. Paclitaxel delivered as a 63-hour infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity
48. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix